• Je něco špatně v tomto záznamu ?

Myc 9aaTAD activation domain binds to mediator of transcription with superior high affinity

A. Knight, J. Houser, T. Otasevic, V. Juran, V. Vybihal, M. Smrcka, M. Piskacek

. 2024 ; 30 (1) : 211. [pub] 20241113

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003464

Grantová podpora
NV19-05-00410 Ministerstvo Vnitra České Republiky

The overexpression of MYC genes is frequently found in many human cancers, including adult and pediatric malignant brain tumors. Targeting MYC genes continues to be challenging due to their undruggable nature. Using our prediction algorithm, the nine-amino-acid activation domain (9aaTAD) has been identified in all four Yamanaka factors, including c-Myc. The predicted activation function was experimentally demonstrated for all these short peptides in transactivation assay. We generated a set of c-Myc constructs (1-108, 69-108 and 98-108) in the N-terminal regions and tested their ability to initiate transcription in one hybrid assay. The presence and absence of 9aaTAD (region 100-108) in the constructs strongly correlated with their activation functions (5-, 3- and 67-times respectively). Surprisingly, we observed co-activation function of the myc region 69-103, called here acetyl-TAD, previously described by Faiola et al. (Mol Cell Biol 25:10220-10234, 2005) and characterized in this study as a new domain collaborating with the 9aaTAD. We discovered strong interactions on a nanomolar scale between the Myc-9aaTAD activation domains and the KIX domain of CBP coactivator. We showed conservation of the 9aaTADs in the MYC family. In summary for the c-Myc oncogene, the acetyl-TAD and the 9aaTAD domains jointly mediated activation function. The c-Myc protein is largely intrinsically disordered and therefore difficult to target with small-molecule inhibitors. For the c-Myc driven tumors, the strong c-Myc interaction with the KIX domain represents a promising druggable target.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003464
003      
CZ-PrNML
005      
20250206104349.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s10020-024-00896-7 $2 doi
035    __
$a (PubMed)39538178
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Knight, Andrea $u School of Life Science, Faculty of Science and Engineering, Anglia Ruskin University, East Road, Cambridge, CB1 1PT, UK. andrea.knight@aru.ac.uk $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University Brno, Masaryk University, Kamenice 753/5, Brno, 625 00, Czech Republic. andrea.knight@aru.ac.uk $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic. andrea.knight@aru.ac.uk $1 https://orcid.org/0000000172917975
245    10
$a Myc 9aaTAD activation domain binds to mediator of transcription with superior high affinity / $c A. Knight, J. Houser, T. Otasevic, V. Juran, V. Vybihal, M. Smrcka, M. Piskacek
520    9_
$a The overexpression of MYC genes is frequently found in many human cancers, including adult and pediatric malignant brain tumors. Targeting MYC genes continues to be challenging due to their undruggable nature. Using our prediction algorithm, the nine-amino-acid activation domain (9aaTAD) has been identified in all four Yamanaka factors, including c-Myc. The predicted activation function was experimentally demonstrated for all these short peptides in transactivation assay. We generated a set of c-Myc constructs (1-108, 69-108 and 98-108) in the N-terminal regions and tested their ability to initiate transcription in one hybrid assay. The presence and absence of 9aaTAD (region 100-108) in the constructs strongly correlated with their activation functions (5-, 3- and 67-times respectively). Surprisingly, we observed co-activation function of the myc region 69-103, called here acetyl-TAD, previously described by Faiola et al. (Mol Cell Biol 25:10220-10234, 2005) and characterized in this study as a new domain collaborating with the 9aaTAD. We discovered strong interactions on a nanomolar scale between the Myc-9aaTAD activation domains and the KIX domain of CBP coactivator. We showed conservation of the 9aaTADs in the MYC family. In summary for the c-Myc oncogene, the acetyl-TAD and the 9aaTAD domains jointly mediated activation function. The c-Myc protein is largely intrinsically disordered and therefore difficult to target with small-molecule inhibitors. For the c-Myc driven tumors, the strong c-Myc interaction with the KIX domain represents a promising druggable target.
650    _2
$a lidé $7 D006801
650    12
$a protoonkogenní proteiny c-myc $x metabolismus $x genetika $7 D016271
650    12
$a vazba proteinů $7 D011485
650    _2
$a proteinové domény $7 D000072417
650    _2
$a aktivace transkripce $7 D015533
650    _2
$a sekvence aminokyselin $7 D000595
655    _2
$a časopisecké články $7 D016428
700    1_
$a Houser, Josef $u Central European Institute of Technology (CEITEC), Masaryk University Brno, Brno, Czech Republic $u National Centre for Biomolecular Research (NCBR), Faculty of Science, Masaryk University Brno, Brno, Czech Republic $u Core Facility Biomolecular Interactions and Crystallization (CF BIC), Masaryk University Brno, Brno, Czech Republic
700    1_
$a Otasevic, Tomas $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University Brno, Masaryk University, Kamenice 753/5, Brno, 625 00, Czech Republic
700    1_
$a Juran, Vilem $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vybihal, Vaclav $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Piskacek, Martin $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University Brno, Masaryk University, Kamenice 753/5, Brno, 625 00, Czech Republic. piskacek@med.muni.cz $1 https://orcid.org/0000000262831542
773    0_
$w MED00003396 $t Molecular medicine (Cambridge, Mass. Print) $x 1528-3658 $g Roč. 30, č. 1 (2024), s. 211
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39538178 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104344 $b ABA008
999    __
$a ok $b bmc $g 2263315 $s 1239471
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 1 $d 211 $e 20241113 $i 1528-3658 $m Molecular medicine (Cambridge, Mass. Print) $n Mol Med $x MED00003396
GRA    __
$a NV19-05-00410 $p Ministerstvo Vnitra České Republiky
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace